<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02163018</url>
  </required_header>
  <id_info>
    <org_study_id>HAL-MPE1/0043</org_study_id>
    <secondary_id>2013-004238-13</secondary_id>
    <nct_id>NCT02163018</nct_id>
  </id_info>
  <brief_title>HAL-MPE1 First-in-human</brief_title>
  <acronym>HAL-MPE1/0043</acronym>
  <official_title>A First-in-human, Randomized, Double Blind, Placebo Controlled, Single-centre Study to Assess the Safety and Tolerability of HAL-MPE1 in Patients With Peanut Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HAL Allergy</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HAL Allergy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, there is no effective causal treatment for peanut allergy. A chemically modified,&#xD;
      aluminium hydroxide adsorbed peanut extract (HAL-MPE1) for subcutaneous administration has&#xD;
      been developed. Results from in vitro and in vivo preclinical studies demonstrate the&#xD;
      immunotherapeutic potential of HAL-MPE1. Therefore, a phase I, single-centre clinical trial&#xD;
      has been designed to assess the safety and tolerability of HAL-MPE1 in peanut allergic&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of a SCIT-treatment with HAL-MPE1 in patients with peanut allergy.</measure>
    <time_frame>up to 20 weeks</time_frame>
    <description>Occurrence of early and late local reactions&#xD;
Occurrence of early and late systemic reactions&#xD;
Occurrence of adverse events (clinically relevant abnormalities of the physical examination will be documented as adverse events)&#xD;
Changes in laboratory values, vital signs, ECG and lung function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum levels of allergen specific immunoglobulins</measure>
    <time_frame>before and after 15-20 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in basophil histamine release test</measure>
    <time_frame>before and after 15-20 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in titrated skin prick test</measure>
    <time_frame>before and after 15-20 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Peanut Allergy</condition>
  <arm_group>
    <arm_group_label>HAL-MPE1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous administration of increasing doses of HAL-MPE1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous administration of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAL-MPE1</intervention_name>
    <description>Subcutaneous administration of increasing doses of HAL-MPE1</description>
    <arm_group_label>HAL-MPE1</arm_group_label>
    <other_name>HAL-MPE1: modified peanut extract</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous administration of increasing doses of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>HAL-MPE1 placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent.&#xD;
&#xD;
          2. Male or female subjects aged 18-65 years.&#xD;
&#xD;
          3. A well-documented medical history of systemic reactions after ingestion of peanut&#xD;
&#xD;
          4. Positive food challenge at ≤1.5 gram peanut protein ingestion within the last 2 years&#xD;
&#xD;
          5. Positive serum specific anti-peanut and Ara h 2 Immunoglobulin E (IgE-test) (&gt;0.7&#xD;
             kiloUnits(kU)/L) within the last 2 years&#xD;
&#xD;
          6. Forced expiratory volume at one second (FEV1)&gt;70% of predicted value&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a history of severe anaphylaxis to peanut with the following symptoms:&#xD;
             hypotension, hypoxia, neurological compromise (collapse, loss of consciousness or&#xD;
             incontinence) during challenge with peanuts.&#xD;
&#xD;
          2. Baseline serum tryptase level &gt;20 µg/l&#xD;
&#xD;
          3. Known allergy or known hypersensitivity to (placebo) excipients&#xD;
&#xD;
          4. Participation in any interventional study aimed at desensitizing the peanut allergy in&#xD;
             the past&#xD;
&#xD;
          5. Any specific immunotherapy (SCIT, SLIT or OIT) during the study period&#xD;
&#xD;
          6. Severe immune disorders (including auto-immune diseases) and/or diseases requiring&#xD;
             immunosuppressive drugs&#xD;
&#xD;
          7. Significant active malignancies or any malignant disease within the past 5 years&#xD;
&#xD;
          8. Severe uncontrolled diseases that could increase the risk for patients participating&#xD;
             in the study, including but not limited to: any severe or unstable lung diseases;&#xD;
             endocrine diseases; clinically significant renal or hepatic diseases, or&#xD;
             haematological disorders; or severe ongoing symptomatic allergic diseases&#xD;
&#xD;
          9. History of cardiovascular disease, uncontrolled hypertension or arrhythmias&#xD;
&#xD;
         10. Diseases with a contraindication for the use of adrenaline (e.g. hyperthyroidism,&#xD;
             glaucoma)&#xD;
&#xD;
         11. Use of systemic steroids within 4 weeks before start of the study and during the study&#xD;
&#xD;
         12. Treatment with β-blockers/ACE inhibitors&#xD;
&#xD;
         13. Vaccination within one week before start of therapy or during study&#xD;
&#xD;
         14. Anti-IgE/anti-Tumor necrosis factor (TNF) therapy or any biologic immunomodulatory&#xD;
             therapy within the 6 months prior to inclusion and during the study&#xD;
&#xD;
         15. Participation in a clinical study with a new investigational drug within the last 3&#xD;
             months or for a biological within the last 6 months prior to or during the study&#xD;
&#xD;
         16. Pregnancy (test performed at screening), lactation or inadequate contraceptive&#xD;
             measures for women of child-bearing age (contraceptive measures considered adequate&#xD;
             are: intrauterine devices, hormonal contraceptives, such as contraceptive pills,&#xD;
             implants, transdermal patches, hormonal vaginal devices or injections with prolonged&#xD;
             release)&#xD;
&#xD;
         17. Alcohol, drug or medication abuse within the past year&#xD;
&#xD;
         18. Any clinically significant abnormal laboratory parameter at screening&#xD;
&#xD;
         19. Lack or expected lack of cooperation or compliance&#xD;
&#xD;
         20. Severe psychiatric, psychological, or neurological disorders&#xD;
&#xD;
         21. Patients who are employees of the sponsor, institution or 1st grade relatives or&#xD;
             partners of the investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carsten Bindslev-Jensen, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hudafdeling I og Allergicentret, Odense Universitetshospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carsten Bindslev-Jensen</name>
      <address>
        <city>Odense</city>
        <zip>DK 5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>June 5, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <last_update_submitted>July 9, 2015</last_update_submitted>
  <last_update_submitted_qc>July 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

